Metacognitive Therapy for Obsessive-Compulsive Disorder

University of Leipzig74 enrolled

Overview

Cognitive behavior therapy is the most effective treatment of obsessive-compulsive disorder. However, the majority of treated patients remain symptomatic. The metacognitive therapy by Wells (1997) could achieve substantial gains in first pilot studies. The purpose of this study is to investigate this approach with a randomized controlled trial by comparing metacognitive therapy with exposure and response prevention for obsessive-compulsive disorder.

The purpose of this study is to investigate metacognitive therapy by Wells (1997) with a randomized controlled trial by comparing metacognitive therapy with exposure and response prevention for obsessive-compulsive disorder.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Obsessive-Compulsive Disorder (OCD)

Interventions

Metacognitive TherapyBEHAVIORAL

Metacognitive Therapy for OCD according to Wells (1997)

Exposure and Response PreventionBEHAVIORAL

Exposure and Response Prevention for OCD according to Kozak \& Foa (1997)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Primary diagnosis: obsessive-compulsive disorder * German-speaking * Agreeing to participate, verified by completion of informed consent * Stable medication (at least 4 weeks) Exclusion Criteria: * Current or past diagnosis of substance dependence, psychosis, neurological conditions * Mental retardation

Locations (2)

Leipzig University

Leipzig, Germany

Philipps University Marburg

Marburg, Germany

Outcomes

Primary Outcomes

Change in Symptom Severity (Yale Brown Obsessive-Compulsive Scale; Y-BOCS)

Time frame: at pretest (admission), after completion of 6 therapeutic sessions (after an expected average of 6 weeks), at posttest after completion of 12 therapeutic sessions (after an expected average of 12 weeks), at follow-up (6 months after end of treatment)

Secondary Outcomes

Change in Symptom Severity (Padua Inventory; PI)

Change in general psychopathology (Symptom Checklist-90-Revised, SCL-90-R)

Change in Metacognitions (Metacognitions Questionnaire, short version, MCQ-30)

Change in Obsessive Beliefs (Obsessive Beliefs Questionnaire, OBQ)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Change in Behavioral Avoidance (Behavioral Avoidance Test, BAT)

Change in Depression (Beck Depression Inventory, BDI-II)

Change in Anxiety (Beck Anxiety Inventory, BAI)

Change in Symptom Severity (Clinical Global Impressions; CGI)

Change in psychosocial functioning (Global Assessment of Functioning Scale, GAF)

Change in quality of life (The World Health Organization Quality of Life, WHOQOL_BREF)

Change in quality of life (The World Health Organization Quality of Life, WHOQOL\_BREF)

Difference in efficiency (length of treatment)

documentation of number of sessions

Time frame: immediately after completion of therapy (after an expected avarage of 12 weeks)

Difference in medical costs (based on the length of treatment)

Time frame: immediately after completion of therapy (after an expected avarage of 12 weeks)

Difference in negative effects of psychotherapy (Inventory for the Assessment of Negative Effects of Psychotherapy, INEP)

Time frame: after completion of 6 therapeutic sessions (after an expected avarage of 6 weeks), at posttest after completion of 12 therapeutic sessions (after an expected avarage of 12 weeks), at follow-up (6 months after end of treatment)

Difference in satisfaction with the treatment

Time frame: immediately after completion of therapy (after an expected avarage of 12 weeks)